Cost-effectiveness of lower targets for blood pressure and low-density lipoprotein cholesterol in diabetes: The Stop Atherosclerosis in Native Diabetics Study (SANDS)

Journal of Clinical Lipidology

Volumn 4, Issue 3, 2010, Pages 165-172

  Wilson, Charlton ^a   Huang, Chun Chih ^b   Shara, Nawar ^b   Howard, Barbara V ^b   Fleg, Jerome L ^c   Henderson, Jeffrey A ^d   Howard, Wm James ^e   Huentelman, Heather ^a   Lee, Elisa T ^f   Mete, Mihriye ^b   Russell, Marie ^a   Galloway, James M ^g   Silverman, Angela ^b   Stylianou, Mario ^c   Umans, Jason ^b   Weir, Matthew R ^h   Yeh, Fawn ^g   Ratner, Robert E ^b  

^a PHOENIX INDIAN MEDICAL CENTER   (United States)

^b MEDSTAR RESEARCH INSTITUTE   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d Black Hills Center for American Indian Health   (United States)

^e WASHINGTON HOSPITAL CENTER   (United States)

^f UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^g NORTHWESTERN UNIVERSITY   (United States)

^h UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Blood pressure; Clinical trial; Cost effectiveness; Diabetes mellitus; Lipids; Quality of well being

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; EZETIMIBE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT;

ADULT; AMERICAN INDIAN; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DATA BASE; DRUG COST; FEMALE; HEALTH CARE COST; HEALTH CARE SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SERVICE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; COST-BENEFIT ANALYSIS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOLIPIDEMIC AGENTS; INDIANS, NORTH AMERICAN; MALE; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; UNITED STATES;

EID: 77956676772     PISSN: 19332874     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacl.2010.01.008     Document Type: Article

References (31)

1. W.B. Kannel, and D.L. McGee Diabetes and glucose tolerance as risk factors for cardiovascular disease: The Framingham Study Diabetes Care 2 1979 120 126
2. J.C. Kleinman, R.P. Donahue, M.I. Harris, F.F. Finucane, J.H. Madans, and D.B. Brock Mortality among diabetics in a national sample Am J Epidemiol 128 1988 389 401
3. W.J. Butler, L.D. Ostrander, W.J. Carman, and D.E. Lamphiear Mortality from coronary heart disease in the Tecumseh Study: long-term effect of diabetes mellitus, glucose tolerance and other risk factors Am J Epidemiol 121 1985 541 547
4. B.V. Howard Macrovascular complications of diabetes mellitus D. LeRoith, S.I. Taylor, J.M. Olefs, Diabetes Mellitus 1996 Lippincott-Raven Philadelphia 792 797
5. R. Klein Kelly West Lecture 1994: hyperglycemia and microvascular and macrovascular disease in diabetes Diabetes Care 18 1995 258 268
6. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
7. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI), NIH Publication No. 98-4080 (1997) [No. 98-4080].
8. K. Pyrälä, T.R. Pedersen, J. Kjekshus, O. Faergeman, A.G. Olsson, and G. Thorgeirsson Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) Diabetes Care 20 1997 614 620
9. A. Keech, D. Colquhoun, and J. Best Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial Diabetes Care 26 2003 2713 2721
10. H.M. Colhoun, D.J. Betteridge, and P.N. Durrington Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 364 2004 685 696
11. R.H. Knopp, M. d'Emden, J.G. Smilde, and S.J. Pocock Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN) Diabetes Care 29 2006 1478 1485
12. G. Viberti, C.E. Mogensen, L.C. Groop, and J.F. Pauls Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group JAMA 271 1994 275 279
13. B. Dahlof, R.B. Devereux, and S.E. Kjeldsen Cardiovascular morbidity and mortality in the Losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol Lancet 359 2002 995 1003 (Pubitemid 34286536)
14. R.O. Estacio, B.W. Jeffers, N. Gifford, and R.W. Schrier Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes Diabetes Care 23 Suppl 2 2000 B54 B64
15. A. Patel, S. MacMahon, J. Chalmers, B. Neal ADVANCE Collaborative Group Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial Lancet 370 2007 829 840
16. B.V. Howard, E.T. Lee, and L.D. Cowan Rising tide of cardiovascular disease in American Indians: The Strong Heart Study Circulation 99 1999 2389 2395
17. B. Howard, M.J. Roman, and J.L. Fleg Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: The Stop Atherosclerosis In Native Diabetics Study (SANDS) JAMA 299 2008 1678 1689
18. M.R. Gold, J.E. Siegel, L.B. Russell, M.C. Weinstein, Cost-Effectiveness in Health and Medicine 1996 Oxford University Press New York
19. W.H. Herman Economic analyses of diabetes interventions: rationale, principles, findings and interpretation Endocrinologist 9 1999 113 117
20. M. Russell, J.L. Fleg, and W.J. Galloway Examination of lower targets for low-density lipoprotein cholesterol and blood pressure in diabetes - the Stop Atherosclerosis in Native Diabetics Study (SANDS) Am Heart J 152 2006 867 875
21. S.M. Grundy, J.I. Cleeman, and C.N. Merz Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239
22. Center for Medicare & Medicaid Services. 2009 Jan 7. Physician Fee Schedule Search Physician Fee Schedule Look-up. Available at: http://www.cms.hhs.gov/PFSlookup/02-PFSSearch.asp. Accessed May 29, 2009.
23. Red Book Wholesale Drug Prices Red Book Pharmacy's Fundamental Reference 2008 Thomson Healthcare Montvale, NJ
24. R.M. Kaplan, T.G. Ganiats, W.J. Sieber, and J.P. Anderson The Quality of Well-Being Scale: critical similarities and differences with SF-36 Int J Qual Health Care 10 1998 509 520
25. J.M. Pyne, W.J. Sieber, K. David, R.M. Kaplan, M.H. Rapaport, and D.K. Williams Use of the quality of well-being self-administered version (QWB-SA) in assessing health-related quality of life in depressed patients J Affect Disord 76 2003 237 247
26. R.M. Kaplan, and J.P. Anderson A general health policy model: update and applications Health Serv Res 23 1988 203 235
27. R.H. Chapman, P.W. Stone, E.A. Sandberg, C. Bell, and P.J. Neumann A comprehensive league table of cost-utility ratios and a sub-table of "panel-worthy studies." Med Decis Making 20 2000 451 467
28. CDC Diabetes Cost-effectiveness Group Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes JAMA 287 2002 2542 2551
29. T.O. Tengs, M.E. Adams, and J.S. Pliskin Five-hundred life-saving interventions and their cost-effectiveness Risk Anal 15 1995 369 390
30. J.D. Graham, K.M. Thompson, S.J. Goldie, M. Segui-Gomez, and M.C. Weinstein The cost-effectiveness of air bags by seating position JAMA 278 1997 1418 1425
31. P. Gaede, P. Vedel, N. Larsen, G.V. Jensen, H.H. Parving, and O. Pedersen Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes N Engl J Med 348 2003 383 393 (Pubitemid 36159355)